Anaphylaxis

Daga Wikipedia, Insakulofidiya ta kyauta.
Anaphylaxis
Description (en) Fassara
Iri hypersensitivity (en) Fassara, allergic response (en) Fassara
side effect (en) Fassara
Specialty (en) Fassara emergency medicine (en) Fassara
immunology (en) Fassara
Medical treatment (en) Fassara
Magani epinephrine (en) Fassara
Identifier (en) Fassara
ICD-10 T78.2
ICD-9 995.0
DiseasesDB 29153
MedlinePlus 000844
eMedicine 000844
MeSH D000707
Anaphylaxis
Angioedema na fuska wanda yaron ba zai iya buɗe idanunsa ba. Wannan abin da ya faru ya faru ne sakamakon bayyanar alerjiAnaphylaxis
Angioedema na fuska wanda yaron ba zai iya buɗe idanunsa ba. Wannan abin da ya faru ya faru ne sakamakon bayyanar alerjiAnaphylaxis
Angioedema na fuska wanda yaron ba zai iya buɗe idanunsa ba. Wannan abin da ya faru ya faru ne sakamakon bayyanar alerji
Rabe-rabe da ma'adanai da waje
SymptomsƘunƙarar ƙaiƙayi, kumburin makogwaro, ƙarancin numfashi, haske,[1]
OnsetFiye da mintuna zuwa sa'o'i[1]
CausesCizon kwari, abinci, magunguna[1]
DiagnosisBisa ga alamu[2]
Similar conditionsAllergic halayen, angioedema, asma exacerbation, carcinoid ciwo[2]
TreatmentEpinephrine, ruwan jijiya[1]
Frequency0.05–2%[3]

Anaphylaxis wani mummunan rashin lafiyar da ke saurin farawa kuma yana iya haifar da mutuwa.[4][5] Yawanci yana haifar da fiye da ɗaya daga cikin masu zuwa: kumburin ƙaiƙayi, kumburin makogwaro ko harshe, gajeriyar numfashi, amai, haske, da ƙarancin hawan jini.[4] Waɗannan alamomin yawanci suna zuwa sama da mintuna zuwa sa'o'i.[4]

Dalilan da aka fi sani sun haɗa da cizon kwari da ƙwari, abinci, da magunguna.[4] Wasu dalilai sun haɗa da bayyanar latex da motsa jiki.[4] Bugu da ƙari, lokuta na iya faruwa ba tare da wani dalili na musamman ba.[4] Tsarin ya ƙunshi sakin masu shiga tsakani daga wasu nau'ikan farin jini waɗanda ke haifar da ko dai tsarin rigakafi ko marasa rigakafi.[6] Bincike ya dogara ne akan bayyanar cututtuka da alamun bayyanar bayan bayyanar da rashin lafiyar.[4]

Babban maganin anaphylaxis shine allurar epinephrine a cikin tsoka, ruwan jijiya, da sanya mutum lebur.[4][7] Ana iya buƙatar ƙarin allurai na epinephrine.[4] Sauran matakan, irin su antihistamines da steroids, sun dace.[4] Ɗaukar epinephrine autoinjector da ganewa game da yanayin ana ba da shawarar ga mutanen da ke da tarihin anaphylaxis.[4]

A duk duniya, an kiyasta 0.05-2% na yawan jama'a suna fuskantar anaphylaxis a wani matsayi na rayuwa.[6] Da alama farashin yana ƙaruwa.[6] Yana faruwa sau da yawa a cikin matasa da mata.[7][8] Na mutanen da ke zuwa asibiti masu fama da anaphylaxis a Amurka kusan kashi 99.7 cikin ɗari suna rayuwa.[9] Kalmar ta fito daga Tsohuwar Hellenanci: ἀνά, romanized: ana, lit. 'da', da Tsohon Girkanci: φύλαξις, romanized: phylaxis, lit. 'kariya'.[10]

Manazarta[gyara sashe | gyara masomin]

  1. 1.0 1.1 1.2 1.3 "Anaphylaxis". National Institute of Allergy and Infectious Diseases. April 23, 2015. Archived from the original on 4 May 2015. Retrieved 4 February 2016.
  2. 2.0 2.1 Caterino, Jeffrey M.; Kahan, Scott (2003). In a Page: Emergency medicine (in Turanci). Lippincott Williams & Wilkins. p. 132. ISBN 9781405103572. Archived from the original on 2017-09-08.
  3. Simons, FE; Ardusso, LR; Bilò, MB; El-Gamal, YM; Ledford, DK; Ring, J; Sanchez-Borges, M; Senna, GE; Sheikh, A; Thong, BY; World Allergy, Organization. (February 2011). "World allergy organization guidelines for the assessment and management of anaphylaxis". The World Allergy Organization Journal. 4 (2): 13–37. doi:10.1097/wox.0b013e318211496c. PMC 3500036. PMID 23268454.
  4. 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 Sampson HA, Muñoz-Furlong A, Campbell RL, et al. (February 2006). "Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium". The Journal of Allergy and Clinical Immunology. 117 (2): 391–7. doi:10.1016/j.jaci.2005.12.1303. PMID 16461139.
  5. Tintinalli, Judith E. (2010). Emergency Medicine: A Comprehensive Study Guide (Emergency Medicine (Tintinalli)). New York: McGraw-Hill Companies. pp. 177–182. ISBN 978-0-07-148480-0.
  6. 6.0 6.1 6.2 Khan, BQ; Kemp, SF (August 2011). "Pathophysiology of anaphylaxis". Current Opinion in Allergy and Clinical Immunology. 11 (4): 319–25. doi:10.1097/ACI.0b013e3283481ab6. PMID 21659865.
  7. 7.0 7.1 The EAACI Food Allergy and Anaphylaxis Guidelines Group (August 2014). "Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology". Allergy. 69 (8): 1026–45. doi:10.1111/all.12437. PMID 24909803.
  8. Lee, JK; Vadas, P (July 2011). "Anaphylaxis: mechanisms and management". Clinical and Experimental Allergy. 41 (7): 923–38. doi:10.1111/j.1365-2222.2011.03779.x. PMID 21668816.
  9. Ma, L; Danoff, TM; Borish, L (April 2014). "Case fatality and population mortality associated with anaphylaxis in the United States". The Journal of Allergy and Clinical Immunology. 133 (4): 1075–83. doi:10.1016/j.jaci.2013.10.029. PMC 3972293. PMID 24332862.
  10. Gylys, Barbara (2012). Medical Terminology Systems: A Body Systems Approach. F.A. Davis. p. 269. ISBN 9780803639133. Archived from the original on 2016-02-05.